scholarly journals Comparison of matrix metalloproteinase-9 and E-cadherin expression in early- and late-onset preeclampsia

2021 ◽  
Vol 40 (3) ◽  
pp. 200-206
Author(s):  
Tjam Diana Samara ◽  
Heri Wibowo ◽  
Isabella Kurnia Liem ◽  
Ani Retno Prijanti ◽  
Andrijono Andrijono
Keyword(s):  
Matrix Metalloproteinase ◽  
Gestational Age ◽  
Late Onset ◽  
Matrix Metalloproteinase 9 ◽  
Trophoblast Invasion ◽  
P Value ◽  
Placental Perfusion ◽  
Villous Trophoblast ◽  
Metalloproteinase 9 ◽  
E Cadherin

BACKGROUNDPreeclampsia (PE) is one of the most common pregnancy complications worldwide. Turnover of villous trophoblast is affected by impaired placental perfusion in preeclampsia. Among the various factors that influence pro and antiangiogenic factors in trophoblast invasion of PE are E-cadherin and matrix metalloproteinase-9 (MMP-9). The current classification scheme differentiates PE into two variants early-onset (EO) and late-onset (LO) PE. The aim of this study was to compare MMP-9 and E-cadherin expression between early- (EO) and late-onset (LO) PE. METHODSThis study used a cross-sectional design involving 26 women with gestational age <34 weeks (EO) and 38 women with gestational age ≥34 weeks (LO) from PE patients. Placentas born to preeclamptic mothers were taken in the form of small pieces of the maternal side to measure the levels of MMP-9 and E-cadherin by the ELISA method. Statistical analysis was assessed using the Mann Whitney and independent t-test with a significant p value <0.05. RESULTSSemiquantitative proteinuria levels were significantly higher in EO-PE group compared to LO-PE group (p=0.000). Mean E-cadherin levels were significant lower in the EO-PE group (125.94 ± 54.22 pg/mg) compared to LO-PE group (157.95 ± 54.12 pg/mg) (p=0.024). However, there was no significance difference in median MMP-9 levels between EO-PE group and LO-PE group (p=0.376). CONCLUSIONThis study demonstrate that E-cadherin had lower levels in preeclampsia patients who gave birth <34 weeks. This study indicated that lower levels of e-cadherin can lead to early delivery in preeclampsia patients.

scholarly journals Expression of Matrix Metalloproteinase-9 in Different Histopathological Variants of Ameloblastoma: A Cross-sectional Study

2021 ◽  
Author(s):  
Revati Shailesh Deshmukh ◽  
Priya Nimish Deo ◽  
Surekha Laxman Chavan ◽  
Prasad Kango
Keyword(s):  
Matrix Metalloproteinase ◽  
Tumour Progression ◽  
Matrix Metalloproteinase 9 ◽  
High Rate ◽  
P Value ◽  
Biological Behaviour ◽  
Cross Sectional ◽  
Intense Staining ◽  
Variable Expression ◽  
Metalloproteinase 9

Introduction: Ameloblastomas are benign and the most common odontogenic neoplasms with many histopathological subtypes depending on the predominant pattern. They are known for their aggressive behaviour. As ameloblastomas have a high rate of recurrence, it is necessary to understand the biological behaviour of these neoplasms. Matrix Metalloproteinase-9 (MMP-9) is an enzyme that belongs to Metalloproteinases family and is known to degrade the Extracellular Matrix (ECM) and facilitate tumour progression. Evaluation of the expression of MMP-9 in ameloblastomas could contribute in understanding its biological behaviour. Aim: To analyse the expression of MMP-9 in different histopathological variants of ameloblastoma. Materials and Methods: A cross-sectional observational study was done in the Department of Oral Pathology and Microbiology, Bharati Vidyapeeth Deemed to be University, Dental College and Hospital, Pune, India. A total of 30 cases were selected for this study. The study was carried out for a duration of two years from April 2018 to April 2020. The MMP-9 expression was studied by immunohistochemical staining. The statistical comparison was done using Chi-square test between groups, p-value <0.05 was considered significant. The data was statistically analysed using Statistical Package for Social Sciences (SPSS) version 22.0, IBM Corporation, USA for MS Windows. Results: A total of 30 paraffin embedded archival tissue blocks were selected for this study. Among them nine cases were of Plexiform Ameloblastoma, eight of Unicystic Ameloblastoma, three of Acanthomatous Ameloblastoma, four of Desmoplastic Ameloblastoma and six were of Follicular Ameloblastomas. The MMP-9 showed variable expression in different histopathological subtypes of ameloblastoma. This difference was statistically significant between Plexiform and Acanthomatous as well as Plexiform and Follicular variants (p<0.05). A 66.7% (6 out of 9 samples) of Plexiform Ameloblastoma showed intense staining for MMP-9. Conclusion: Expression of MMP-9 varies in different histopathological variants of ameloblastoma and may not have an association with biological behaviour and aggressiveness.

scholarly journals Matrix metalloproteinase-9 (MMP-9) as prospective histopathological and molecular biomarker for oral squamous cell carcinoma

2018 ◽  
Vol 6 (8) ◽  
pp. 2801
Author(s):  
Bhagyalakshmi Atla ◽  
Sreevalli Prabhakula ◽  
Seeram Satish Kumar ◽  
Lakshmi Saraswathi Boni
Keyword(s):  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Matrix Metalloproteinase ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Treatment Strategies ◽  
Matrix Metalloproteinase 9 ◽  
P Value ◽  
Female Ratio ◽  
Metalloproteinase 9

Background: Despite the advance of therapeutic approaches, the morbidity and mortality of oral squamous cell carcinoma have not improved significantly. The invasion potential of oral squamous cell carcinoma is conferred by their ability to utilize Matrix metalloproteinase that are produced by the host’s stromal cells. In the present study an effort was made to analyse the role of clinical features and risk factors in the causation of oral squamous cell carcinoma and expression of Matrix metalloproteinase-9 (MMP-9) was studied in various grades of squamous cell carcinoma with its role in metastasis.Methods: The present study is an hospital based prospective study for a period of two years at the department of pathology from August 2014 to July 2016 consisting of 88 cases of oral squamous cell carcinoma. Tissue for H and E sections were fixed in 10% formalin and subjected to routine paraffin embedded processing and stained with hematoxylin and eosin.Results: Total number of cases of oral squamous cell carcinoma analyzed were 88, out of which 65 cases were subjected to MMP 9 expression by random selection on Immunohistochemistry. Majority of cases occurred in the age group of 41-50 years with male: female ratio of 1.4:1. In stage I and II the expression of MMP-9 is low in 37 cases (82.22%) and in stage III the expression is high in 14 cases (70%) with P value <0.05 (significant).Conclusions: Matrix metalloproteinases could act as a therapeutic target and could play an important role in effective treatment strategies of oral cancer.

scholarly journals A Comparative Study of Serum Matrix Metalloproteinase-9 in Tuberculous Meningitis With and Without Stroke

2019 ◽  
pp. 37-41
Author(s):  
Rajat Jhamb ◽  
Amit Kumar Gauraw ◽  
Rajarshi Kar ◽  
Priyanka Gogoi ◽  
Rajnish Avasthi
Keyword(s):  
Matrix Metalloproteinases ◽  
Matrix Metalloproteinase ◽  
Tuberculous Meningitis ◽  
Extrapulmonary Tuberculosis ◽  
Matrix Metalloproteinase 9 ◽  
P Value ◽  
Elisa Method ◽  
Radiological Findings ◽  
Duration Of Illness ◽  
Metalloproteinase 9

Background: Tuberculous meningitis is defined as an inflammatory response to mycobacterial bacterial infection of the pia, arachnoid and CSF of the subarachnoid space. It is a dangerous form of extrapulmonary tuberculosis because it can cause permanent neurological disabilities and even death. Stroke is a devastating complication which further increase the morbidity and mortality in the disease. Matrix metalloproteinases are endopeptidases which degrade all the components of the extracellular matrix and thus have potential to disrupt blood brain barrier and cause CNS damage. Matrix metalloproteinases have been associated with pathophysiology of ischemic stroke. MMP levels in serum and CSF have also been seen to rise with advancing stage of TBM. So it is postulated that MMP may have role in the pathophysiology of stroke in TBM and may serve as a biomarker to predict stroke in TBM. Aims: To compare Serum Matrix metalloproteinase-9 in patients with Tuberculous Meningitis with and without Stroke and correlate it with various clinical, biochemical and radiological features of TBM. Methods: 40 Patients of probable or definite TBM and 40 age and sex matched patients of TBM with clinical stroke were enrolled in the study and formed two groups i.e. cases and controls. The two groups were compared for various clinical parameters, biochemical parameters (CSF cytology, glucose and protein), neuroimaging parameters and serum MMP-9 levels. Serum MMP-9 was estimated by ELISA method. Results: Serum MMP-9 levels were (224 ± 261.627 ng/ml) in cases and (157.23 ± 197.155 ng/ml) controls, which though higher in cases but no difference was statistically significant (p value 0.157) between two groups. Also there was no correlation between the serum MMP-9 levels and various clinical features (duration of illness, fever, headache, vomiting, weight loss, seizure, hemiparesis), CSF characteristics (protein, sugar and cytology) and radiological findings (tuberculoma, and hydrocephalus). Conclusion: we conclude that MMP-9 levels is not correlated with occurrence of stroke in TBM. MMP-9 levels were not increased with severity of disease, complications and outcomes.

scholarly journals Relationships of MMP-9, E-cadherin, and VEGF expression with clinicopathological features and response to chemosensitivity in gastric cancer

Tumor Biology ◽  
2017 ◽  
Vol 39 (5) ◽  
pp. 101042831769836 ◽  
Author(s):  
Hongyu Gao ◽  
Xiuwen Lan ◽  
Sen Li ◽  
Yingwei Xue
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Matrix Metalloproteinase ◽  
Collagen Gel ◽  
Matrix Metalloproteinase 9 ◽  
Vascular Endothelial ◽  
Positive Expression ◽  
Endothelial Growth Factor ◽  
Metalloproteinase 9 ◽  
E Cadherin

The matrix metalloproteinase-9, E-cadherin, and vascular endothelial growth factor play an important role in behavior of tumor cell growth, invasion, and metastasis. In this study, we investigated the relationships of matrix metalloproteinase-9, E-cadherin, and vascular endothelial growth factor expression with clinicopathological features and results of chemosensitivity tested by collagen gel droplet–embedded culture–drug sensitivity test in gastric cancer. Fresh specimens were used for collagen gel droplet–embedded culture–drug sensitivity test and paired fixed specimens were used for immunohistochemistry. Positive expression of matrix metalloproteinase-9 was associated with poorly differentiated carcinoma (p = 0.032), lymph node metastasis (p = 0.022), and tumor stage (p = 0.023). Negative expression of E-cadherin was associated with poorly differentiated carcinoma (p = 0.007), lymph node metastasis (p = 0.012), and tumor stage (p = 0.007). Positive expression of vascular endothelial growth factor was associated with tumor size (p = 0.040) and stage (p = 0.007). Collagen gel droplet–embedded culture–drug sensitivity test was successfully evaluated in 56 patients. Among them, 29 (51.7%) patients were resistant to TS-1 and 31 (55.3%) patients were resistant to L-OHP. The L-OHP resistance rate in vascular endothelial growth factor positive patients was significantly higher than that in negative patients (p = 0.031). The L-OHP resistance rate in E-cadherin negative patients was significantly higher than that in positive patients (p = 0.014). In conclusion, matrix metalloproteinase-9, E-cadherin, and vascular endothelial growth factor were involved in tumor invasion and metastasis. Positive expression of matrix metalloproteinase-9 and vascular endothelial growth factor and negative expression of E-cadherin were malignant markers for gastric cancer. Positive expression of vascular endothelial growth factor and negative expression of E-cadherin were associated with L-OHP resistance.

scholarly journals Cullin 1 is not associated with late-onset preeclampsia

2019 ◽  
Vol 38 (1) ◽  
pp. 4
Author(s):  
Tjam Diana Samara ◽  
Isabella Kurnia Liem ◽  
Ani Retno Prijanti ◽  
Andrijono Andrijono
Keyword(s):  
Gestational Age ◽  
Late Onset ◽  
Placental Tissue ◽  
Trophoblast Invasion ◽  
P Value ◽  
Cross Sectional ◽  
Median Serum ◽  
Spearman Correlation Test ◽  
Elisa Technique ◽  
Cross Sectional Design

Background<br />Late-onset preeclampsia (PE) is preeclampsia occurring after 34 weeks of gestational age or later.  Cullin 1 (CUL1), a proangiogenic protein, is expressed in the placenta, where an imbalance between proangiogenic and antiangiogenic proteins during gestation can cause disturbance of trophoblast invasion. This defect results in vascular ischemia that may produce preeclampsia. The objective of this study was to determine the correlation between CUL1 as proangiogenic factor and late-onset preeclampsia. <br /><br />Methods<br />This study was of analytical observational cross-sectional design and involved 44 preeclampsia patients with ³34 weeks of gestational age (late-onset PE). The CUL1 level in the subjects’ sera, taken before they gave birth, and in homogenates of their placenta, obtained per vaginam or by cesarean section, were examined by the ELISA technique.  Statistical analysis was performed with the Spearman correlation test with significant p value of &lt;0.05.<br /><br />Results<br />Median maternal age was 31 years and median gestational age was 37 weeks.  Median serum CUL1 was 41.78 pg/mL and median placental homogenate CUL1 was 32.24 pg per milligram of total placental tissue protein. There was no significant correlation between serum CUL1 level and late-onset preeclampsia (r=-0.281; p=0.065). There was also no significant correlation between placental CUL1 level and late-onset preeclampsia (r=-0.166; p=0.281).<br /><br />Conclusion<br />Serum CUL1 and placental CUL1 were not correlated with late-onset preeclampsia. However, this study indicated that low serum CUL1 tends to prolong gestational age in preeclampsia.

Sign in / Sign up

Export Citation Format

Share Document